menubar

Friday, July 31, 2020

Good News for Humanity | ReMag Study

Here's the published study on our ReMag (the first of many):


Circulating Ionized Magnesium as a Measure of Supplement Bioavailability: Results from a Pilot Study for Randomized Clinical Trial

A placebo and crossover blinded control study.

Talking points:

1. iMg (ionized magnesium testing) is the better marker for magnesium. Serum magnesium is bound up and not usable. Magnesium ions are available to use in the cells.

2. Using a molecular size analyzer (Malvern Zetasizer Nano ZS, Malvern, UK), we confirmed that the majority of the particle size of ReMag® formulation is in the picometer range. The test was repeated three times.

3. ReMag goes to the ionized magnesium status and is not bound up. Its small size allows it to be absorbed higher up in the GI tract and avoid the laxative effect.

4. Magnesium oxide and magnesium citrate are less bioavailable and larger in size compared to ReMag, thus they do not affect ionized magnesium as efficiently.

5. Elevated ionized magnesium was measurable in the blood within 2-4 hours. Our head of research, Dr. Taylor Wallace said that this fluctuation with one single dose is very important. He said he would not have anticipated mineral electrolytes changing with 1 single dose.

6. Clinical investigations have demonstrated that ionized magnesium, but not serum magnesium, is depressed in a number of clinical conditions such as migraine, individuals with noninsulin-dependent diabetes, patients with asthma, and women with high-risk pregnancies.

7. A subclinical magnesium deficiency can occur when serum magnesium levels are within the lower reference range. Therefore, serum total magnesium levels may not be sufficient for diagnosis of deficiency.

8. Our findings of a more robust ionized response, when compared to serum magnesium, are similar to those reported by Altura et al.


Below: Listen to the audio recording of our recent conversation with the leader of the research team, Dr. Taylor Wallace.

15 June 2020

No comments: